Phil Febbo, MD

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.